Source: Annual Congress 2007 - Venous thromboembolic disease
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Kosma, A. Antoniadis, G. Koundi, G. Voudrislis, E. Markopoulou, E. Kalaitzidou, N. Galanis (Thessaloniki, Serres, Greece). Comparison between the administration of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in the treatment of pulmonary embolism. Eur Respir J 2007; 30: Suppl. 51, 3558

Member's Comments

No comment yet.

Related content which might interest you: One hour alteplase infusion plus low molecular weight heparin versus heparin alone in pulmonary embolism Source: Annual Congress 2003 - Pulmonary hypertension Year: 2003 Long term treatment of pulmonary embolism (PE) with low molecular weight heparin (LMWH) (tinzaparin). Preliminary results Source: Eur Respir J 2007; 30: Suppl. 51, 80s Year: 2007 Low-molecular-weight heparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2001; 18: Suppl. 33, 381s Year: 2001 Enoxaparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002 Comparison of low-molecular-weight-heparin and unfractionated heparin for acute PTE Source: Eur Respir J 2005; 26: Suppl. 49, 699s Year: 2005 Randomized trial of low-molecular-weight heparin compared with unfractionated heparin for acute pulmonary embolism Source: Eur Respir J 2001; 18: Suppl. 33, 382s Year: 2001 Effectiveness of anticoagulation with unfractionated heparin for acute pulmonary embolism Source: Virtual Congress 2021 – Insights into pulmonary embolism Year: 2021 Pulmonary embolism and pregnancy Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=177 Year: 2004 Successful heparin desensitization after anaphylactic shock due to low molecular weight heparin Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005 Possible anti-inflammatory activity of low molecular weight heparin in patients with high risk of pulmonary embolism Source: Eur Respir J 2004; 24: Suppl. 48, 684s Year: 2004 Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020 Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin. Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019 Early discharge of patients with pulmonary embolism: a two-phase observational study Source: Eur Respir J 2007; 30: 708-714 Year: 2007 Treatment of VTE during pregnancy with a once-daily regimen of LMWH Source: Annual Congress 2007 - Acute and chronic pulmonary embolism Year: 2007 A single centre experience of low dose direct oral anticoagulants (DOAC) after unprovoked venous thromboembolism (VTE) Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019 Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019 Anti-inflammatory activity of low molecular weight heparin in patients with exacerbations of COPD Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Comparison of long –term outcomes of 50 mg rt-PA and 100 mg rt-PA in the management of acute pulmonary embolism Source: International Congress 2016 – Acute pulmonary embolism Year: 2016 Thromboprophylaxis in lung cancer patients with intermediate tinzaparin dose: The iCaLT study Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 The treatment of sub massive pulmonary embolism: Thrombolytic or heparin? Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism Year: 2012